Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICPIs) are being investigated in clinical trials for patients with glioblastoma. While these therapies hold great promise, management of the patients receiving such treatment can be complicated due to the challenges in recognizing immune-related adverse events caused by checkpoint inhibitor treatment. Brain imaging changes that are the consequence of an inflammatory response may be misinterpreted as disease progression leading to inappropriate premature cessation of treatment. The aim of this study was to, by way of a series of cases, underscore the challenges in determining the nature of contrast-enhancing masses that develop during the treatment of patients with glioblastoma treated with ICPIs.

Case presentation

We reviewed the clin

SUBMITTER: Ranjan S 

PROVIDER: S-EPMC5831705 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature